CN110023318A - 化合物的晶型 - Google Patents

化合物的晶型 Download PDF

Info

Publication number
CN110023318A
CN110023318A CN201780074441.8A CN201780074441A CN110023318A CN 110023318 A CN110023318 A CN 110023318A CN 201780074441 A CN201780074441 A CN 201780074441A CN 110023318 A CN110023318 A CN 110023318A
Authority
CN
China
Prior art keywords
degree
cancer
crystal form
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780074441.8A
Other languages
English (en)
Inventor
吴振平
李文姬
储玉平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CN110023318A publication Critical patent/CN110023318A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本发明属于药学领域，提供了化合物(3aR,6aR)‑N‑(4‑(3‑乙炔基苯氨基)‑7‑甲氧基喹唑啉‑6‑基)‑1‑甲基‑六氢吡咯并[3,4‑b]吡咯‑5(1H)‑甲酰胺的晶型、其药物组合物，及其制备方法和应用。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN201780074441.8A 2016-12-01 2017-12-01 化合物的晶型 Pending CN110023318A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611089802 2016-12-01
CN201611089802X 2016-12-01
PCT/CN2017/114194 WO2018099451A1 (zh) 2016-12-01 2017-12-01 化合物的晶型

Publications (1)

Publication Number Publication Date
CN110023318A true CN110023318A (zh) 2019-07-16

Family

ID=62241231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780074441.8A Pending CN110023318A (zh) 2016-12-01 2017-12-01 化合物的晶型

Country Status (3)

Country Link
CN (1) CN110023318A (zh)
TW (1) TW201833112A (zh)
WO (1) WO2018099451A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021073494A1 (en) * 2019-10-14 2021-04-22 Hutchison Medipharma Limited The salts of a compound and the crystalline forms thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000182A1 (en) * 2010-06-30 2012-01-05 Hutchison Medipharma Limited Quinazoline compounds
CN102311438A (zh) * 2010-06-30 2012-01-11 和记黄埔医药（上海）有限公司 喹唑啉化合物
CN102906086A (zh) * 2010-06-30 2013-01-30 和记黄埔医药（上海）有限公司 喹唑啉化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000182A1 (en) * 2010-06-30 2012-01-05 Hutchison Medipharma Limited Quinazoline compounds
CN102311438A (zh) * 2010-06-30 2012-01-11 和记黄埔医药（上海）有限公司 喹唑啉化合物
CN102906086A (zh) * 2010-06-30 2013-01-30 和记黄埔医药（上海）有限公司 喹唑啉化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021073494A1 (en) * 2019-10-14 2021-04-22 Hutchison Medipharma Limited The salts of a compound and the crystalline forms thereof

Also Published As

Publication number Publication date
WO2018099451A1 (zh) 2018-06-07
TW201833112A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
US11684620B2 (en) Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
EP2244712B1 (en) In vivo studies of crystalline forms of meloxicam
JP2018515569A (ja) キナーゼを調節するための化合物の固体形態
WO2010081443A2 (en) Dosage forms of tyrosine kinase inhibitors
CN106604919B (zh) 6-((6,7-二甲氧基喹唑啉-4-基)氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
RU2300535C2 (ru) Полиморфная форма кристаллического гидрохлорида иринотекана, способ ее получения и фармацевтическая композиция на ее основе
CN109640970A (zh) 具有内皮稳定化活性和抗炎活性的非催化底物选择性p38α特异性MAPK抑制剂及其使用方法
Fan et al. Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
CN109641851A (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
CN112047892A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
CN110446705A (zh) (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式
JP2023022190A (ja) 癌治療
CN108368115B (zh) 吡咯并嘧啶化合物的盐
CN108602779A (zh) 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
CN107362166B (zh) 四氢吡啶并[4,5-]噻吩并[2,3-]嘧啶-4(3)-酮类化合物在制药中的应用
CN110023318A (zh) 化合物的晶型
CN105829323B (zh) Gdc-0032的多晶型物、其制备方法和药物用途
US9018242B2 (en) Salt form of tyrosine kinase inhibitor
CN104292242B (zh) 噻吩嘧啶类化合物和制剂及其制备方法和应用
CN103841828B (zh) 德尼布林二盐酸盐
TWI814468B (zh) 藥用組合物、其製備方法及用途
CN110386937A (zh) 化合物的晶型和无定型
US20230390288A1 (en) Solid dose pharmaceutical composition
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
CN108863951A (zh) 化合物的盐及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190716